Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson’s Disease

Endpoints News Honors Aspen Neuroscience Co-Founder Dr. Jeanne Loring in “20 Women Breaking New Ground”

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences

Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

Endpoints News: Stem cell startup spun out of George Church’s lab raises $75M

BioPharma Dive: Startup from George Church’s lab raises $75M to develop ‘supercell’ medicines

FierceBiotech: From ‘science fiction to reality’: New George Church-founded biotech raises $75M for cell therapy platform